CA1102694A - Traduction non-disponible - Google Patents

Traduction non-disponible

Info

Publication number: CA1102694A
Authority: CA; Canada
Prior art keywords: iii; fractions; percent; albumin; precipitates
Prior art date: 1977-01-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA295,681A

Other languages

English (en)

Inventor

Markus Radowitz

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Armour Pharmaceutical Co

Original Assignee

Armour Pharmaceutical Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1977-01-26

Filing date

1978-01-25

Publication date

1981-06-09

1978-01-25 Application filed by Armour Pharmaceutical Co filed Critical Armour Pharmaceutical Co

1981-06-09 Application granted granted Critical

1981-06-09 Publication of CA1102694A publication Critical patent/CA1102694A/fr

Status Expired legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 46
239000000203 mixture Substances 0.000 title claims abstract description 39
102000004506 Blood Proteins Human genes 0.000 title claims abstract description 26
108010017384 Blood Proteins Proteins 0.000 title claims abstract description 26
238000001990 intravenous administration Methods 0.000 title claims abstract description 9
102000004169 proteins and genes Human genes 0.000 claims abstract description 20
108090000623 proteins and genes Proteins 0.000 claims abstract description 20
239000002244 precipitate Substances 0.000 claims abstract description 19
102000009027 Albumins Human genes 0.000 claims abstract description 15
108010088751 Albumins Proteins 0.000 claims abstract description 15
102000006395 Globulins Human genes 0.000 claims abstract description 15
108010044091 Globulins Proteins 0.000 claims abstract description 15
239000006228 supernatant Substances 0.000 claims abstract description 15
238000005194 fractionation Methods 0.000 claims abstract description 13
238000002360 preparation method Methods 0.000 claims abstract description 13
210000002381 plasma Anatomy 0.000 claims abstract description 10
239000002904 solvent Substances 0.000 claims abstract description 10
239000000644 isotonic solution Substances 0.000 claims abstract description 3
239000012460 protein solution Substances 0.000 claims abstract description 3
102000015081 Blood Coagulation Factors Human genes 0.000 claims abstract 2
108010039209 Blood Coagulation Factors Proteins 0.000 claims abstract 2
239000003114 blood coagulation factor Substances 0.000 claims abstract 2
238000002156 mixing Methods 0.000 claims abstract 2
230000000087 stabilizing effect Effects 0.000 claims abstract 2
239000000243 solution Substances 0.000 claims description 20
239000000126 substance Substances 0.000 claims description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
239000000047 product Substances 0.000 claims description 9
239000007787 solid Substances 0.000 claims description 7
239000003463 adsorbent Substances 0.000 claims description 6
235000012239 silicon dioxide Nutrition 0.000 claims description 6
102000004895 Lipoproteins Human genes 0.000 claims description 5
108090001030 Lipoproteins Proteins 0.000 claims description 5
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims description 4
IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 claims description 3
239000013049 sediment Substances 0.000 claims description 3
239000007853 buffer solution Substances 0.000 claims description 2
125000005624 silicic acid group Chemical class 0.000 claims description 2
230000001376 precipitating effect Effects 0.000 claims 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
210000004369 blood Anatomy 0.000 description 14
239000008280 blood Substances 0.000 description 14
239000007788 liquid Substances 0.000 description 11
210000002966 serum Anatomy 0.000 description 11
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
229920001223 polyethylene glycol Polymers 0.000 description 8
238000001914 filtration Methods 0.000 description 7
239000002202 Polyethylene glycol Substances 0.000 description 6
239000000470 constituent Substances 0.000 description 6
238000000502 dialysis Methods 0.000 description 6
239000012141 concentrate Substances 0.000 description 5
235000008504 concentrate Nutrition 0.000 description 5
229910002012 Aerosil® Inorganic materials 0.000 description 4
108060003951 Immunoglobulin Proteins 0.000 description 4
102000018358 immunoglobulin Human genes 0.000 description 4
235000019624 protein content Nutrition 0.000 description 4
238000000746 purification Methods 0.000 description 4
239000007858 starting material Substances 0.000 description 4
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
102000004338 Transferrin Human genes 0.000 description 3
108090000901 Transferrin Proteins 0.000 description 3
241000700605 Viruses Species 0.000 description 3
238000010586 diagram Methods 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000000463 material Substances 0.000 description 3
238000011084 recovery Methods 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000012581 transferrin Substances 0.000 description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
108010032608 Cohn fraction IV Proteins 0.000 description 2
240000003550 Eusideroxylon zwageri Species 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000000440 bentonite Substances 0.000 description 2
229910000278 bentonite Inorganic materials 0.000 description 2
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
239000003792 electrolyte Substances 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
238000000665 Cohn process Methods 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000007584 Prealbumin Human genes 0.000 description 1
108010071690 Prealbumin Proteins 0.000 description 1
238000013019 agitation Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
239000003914 blood derivative Substances 0.000 description 1
210000001772 blood platelet Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000005352 clarification Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
230000002070 germicidal effect Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
BTIJJDXEELBZFS-UHFFFAOYSA-K hemin Chemical compound [Cl-].[Fe+3].[N-]1C(C=C2C(=C(C)C(C=C3C(=C(C)C(=C4)[N-]3)C=C)=N2)C=C)=C(C)C(CCC(O)=O)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 BTIJJDXEELBZFS-UHFFFAOYSA-K 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000002642 intravenous therapy Methods 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
230000000050 nutritive effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
239000007981 phosphate-citrate buffer Substances 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000008279 sol Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
230000002227 vasoactive effect Effects 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000008979 vitamin B4 Nutrition 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Landscapes

Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA295,681A 1977-01-26 1978-01-25 Traduction non-disponible Expired CA1102694A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CH934/77		1977-01-26
CH93477		1977-01-26

Publications (1)

Publication Number	Publication Date
CA1102694A true CA1102694A (fr)	1981-06-09

Family

ID=4198565

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA295,681A Expired CA1102694A (fr)	1977-01-26	1978-01-25	Traduction non-disponible

Country Status (1)

Country	Link
CA (1)	CA1102694A (fr)

1978
- 1978-01-25 CA CA295,681A patent/CA1102694A/fr not_active Expired

Legal Events

Date	Code	Title	Description
1998-06-09	MKEX	Expiry

Publication	Publication Date	Title
US4216205A (en)	1980-08-05	Process of preparing a serum protein composition for intravenous application
EP0440483B1 (fr)	1997-08-27	Procédé de préparation d'immunoglobulines de sérum
CA2557229C (fr)	2012-07-10	Procede de realisation d'une preparation anticorps avirale purifiee
EP0246579B1 (fr)	1993-08-04	Méthode de production de préparations d'immunoglobuline pour injection intraveineuse
JP2008500959A (ja)	2008-01-17	ウイルスについて安全な免疫グロブリンの製造方法
JPS5944320A (ja)	1984-03-12	Ｃ１不活性化剤の調製方法
US20030078384A1 (en)	2003-04-24	Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
JP2004269529A (ja)	2004-09-30	フィブリノゲン溶液中のウイルスを除去する方法およびこの方法により得られるフィブリノゲン
EP0512883A1 (fr)	1992-11-11	Concentré de facteur XI de la coagulation sanguine à haute activité spécifique, approprié à un usage thérapeutique et son procédé de préparation
EP0825998B1 (fr)	2003-04-09	Preparation de l'immunoglobuline
CA1216792A (fr)	1987-01-20	Methode pour inactiver les substances qui causent des reactions d'incompatibilite
CA1102694A (fr)	1981-06-09	Traduction non-disponible
JPH04346934A (ja)	1992-12-02	γ−グロブリンの液状製剤
JP2000503644A (ja)	2000-03-28	ＩｇＧおよびＩｇＡを単離する方法
RU2158137C1 (ru)	2000-10-27	Способ получения иммуноглобулинового препарата
KR20230024885A (ko)	2023-02-21	간소화된 고효율 단백질 단리를 위한 조성물 및 방법 (compositions and methods for simplified high efficiency isolation of proteins)
CN117946970A (zh)	2024-04-30	一种高品质人血清纯化方法
JPH0381229A (ja)	1991-04-05	抗ａｔｌウイルス抗体陽性静注用免疫グロブリン製剤の製造方法
JPH08231406A (ja)	1996-09-10	血液製剤
JPH07103045B2 (ja)	1995-11-08	非化学修飾γ−グロブリンの加熱処理方法